Brian C. Stephenson - 16 Feb 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Secretary, Treasurer & CFO
Issuer ticker: BBIO
Reported as of: 16 Feb 2025
Net transaction value: -$607,233
SEC form: 4
Accepted by SEC: 19 Feb 2025, 20:50:47 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 27 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/Brian C. Stephenson

Key filing fact

Brian C. Stephenson filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 Feb 2025.

Key facts

This page summarizes Brian C. Stephenson's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 19 Feb 2025, 20:50.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: -$607,233.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,798
Change %: +27%
Price
Shares after: 119,714
Date: 16 Feb 2025
Ownership: Direct
Footnotes: F1, F2

BBIO transaction

Common Stock

Tax liability

Transaction value: $457,260
Shares: -13,102
Change %: -11%
Price: $34.90
Shares after: 106,612
Date: 16 Feb 2025
Ownership: Direct
Footnotes: F3

BBIO transaction

Common Stock

Sale

Transaction value: $149,973
Shares: -4,148
Change %: -3.9%
Price: $36.16
Shares after: 102,464
Date: 19 Feb 2025
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -779
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 779
Exercise price
Footnotes: F1, F6

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -946
Change %: -25%
Price: $0.000000
Shares after: 2,840
Date: 16 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 946
Exercise price
Footnotes: F1, F7

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -17,368
Change %: -11%
Price: $0.000000
Shares after: 138,947
Date: 16 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,368
Exercise price
Footnotes: F1, F8

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -6,705
Change %: -7.7%
Price: $0.000000
Shares after: 80,459
Date: 16 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,705
Exercise price
Footnotes: F1, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

Includes 158 shares of the Issuer's Common Stock acquired by the Reporting Person on February 14, 2025 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

Footnote F3

Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,798 shares of Common Stock underlying the Reporting Person's RSUs.

Footnote F4

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

Footnote F5

Represents the weighted average sale price of the shares sold from $35.57 to $36.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F6

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vested on a quarterly basis. The RSUs have no expiration date.

Footnote F7

The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F8

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F9

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.